Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow expected to be available soon

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc., developer of pioneering technologies to empower science, today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240206284355/en/

“Element continues to expand its customer base, bringing high quality and cost-effective sequencing to researchers globally. Pairing Twist’s robust NGS workflows with Element’s AVITI technology will offer customers an economical and streamlined approach to next generation sequencing,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Because our tools are sequencer agnostic, we can extend the reach of our products with innovative companies like Element, and continue our commitment to empowering researchers to accelerate breakthroughs in scientific discovery by providing advanced tools.”

“We’ve laid out an ambitious product roadmap for 2024 to redefine what is possible on a sequencer and make it even easier for labs to produce the highest quality data at a low cost,” said Molly He, Ph.D., CEO and co-founder of Element Biosciences. “With the Twist for Element Exome Workflow, we are able to provide our customers with easy access to Twist’s Exome 2.0 panel and high performing library preparation and target enrichment reagents, saving them potential downstream sequencing costs by reducing per sample sequencing requirements.”

The Twist for Element Exome Workflow is a purpose-built solution for Element’s AVITI chemistry, alleviating the need for additional workflow steps for linear library conversion. The workflow will include Twist’s library preparation and target enrichment bundled with the Exome 2.0 and comprehensive spike-in. The Exome 2.0 delivers best-in-class sequencing due to its high uniformity and low off-target rate. It is designed to detect rare and inherited diseases, as well as germline cancers.

If interested in learning more about the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow, please reach out here.

About Element Biosciences, Inc.

Element Biosciences is a multi-disciplinary life science company focused on developing disruptive DNA sequencing and other omics technology for research markets. Through innovating every fundamental element of a sequencing system, Element empowers customers with affordable, high-quality data and an improved user experience, which in turn will accelerate scientific discoveries and broaden the use of genomic research. To learn more about Element, please visit www.elementbiosciences.com and follow us on LinkedIn and Facebook.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube | Instagram

Twist Bioscience Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the ability of the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow to save researchers potential downstream sequencing costs by reducing per sample sequencing requirements. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to achieve the expected benefits of Twist Bioscience’s restructuring activities and reduced investments in DNA data storage; the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist Bioscience to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of significant customers; the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits from acquisitions; supply chain and other disruptions; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 2, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240206284355/en/